Last reviewed · How we verify
AZD9567
AZD9567 is a small molecule that inhibits the activity of the PI3K delta subunit.
AZD9567 is a small molecule that inhibits the activity of the PI3K delta subunit. Used for Relapsed or refractory chronic lymphocytic leukemia (CLL).
At a glance
| Generic name | AZD9567 |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | PI3K delta inhibitor |
| Target | PI3K delta |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
This inhibition leads to a reduction in the activation of downstream signaling pathways, which can contribute to the development of various diseases. By targeting the PI3K delta subunit, AZD9567 aims to modulate the immune response and potentially treat certain types of cancer.
Approved indications
- Relapsed or refractory chronic lymphocytic leukemia (CLL)
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
Key clinical trials
- Study to Assess the Effect on Glucose Homeostasis of Two Dose Levels of AZD9567, Compared to Prednisolone, in Adults With Type 2 Diabetes (PHASE2)
- Early Phase Study to Assess Efficacy and Safety of AZD9567 Versus Prednisolone in Patients With Rheumatoid Arthritis (PHASE2)
- A Single Ascending Dose Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of AZD9567. (PHASE1)
- A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of AZD9567. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD9567 CI brief — competitive landscape report
- AZD9567 updates RSS · CI watch RSS
- AstraZeneca portfolio CI